Hims & Hers Health stock gains about 3.5% after strong Q2 results and bullish technicals

Traders Union
All News
Stocks
Hims & hers health surges 3.42% today

Highlights

Hims & Hers Health reported Q2 2026 revenue of $753 million, up 38% year over year and above prior guidance.
The company saw subscriber count rise 19% to 2.89 million and monthly revenue per subscriber increase 21% to $92.
Shares of Hims & Hers Health trade in a prevailing uptrend, with price expected between $30.07 to $35.83 in the next five days and mixed momentum readings indicating overbought conditions.

Subscriber surge and new partnerships bolster earnings momentum

Hims & Hers Health reported strong Q2 2026 financial results, with revenue reaching $753 million, a 38% year-over-year increase and above previous guidance. The number of subscribers grew by 19% to 2.89 million, and monthly revenue per average subscriber rose 21% to $92. Adjusted EBITDA for the quarter was $60.3 million. The company is also exploring partnerships in diagnostics and wearable health devices.

Anton Kharitonov, expert at Traders Union, believes the optimistic headlines mask deeper concerns for Hims & Hers. He notes that despite robust revenue and subscriber growth, momentum signals are diverging. Technicals show overbought conditions and the MACD's Strong Sell is alarming. Price action is near resistance at $33.14 but volatility remains high. "Given weak momentum and overstretched indicators, I see elevated risk for a correction if the price fails to break out above resistance," says Kharitonov.

Viktoras Karapetjanc, expert at Traders Union, sees substantial opportunity in Hims & Hers as the bullish structure remains strong. He highlights impressive revenue growth of 38% and rising subscriber engagement. The company’s new partnerships in diagnostics and wearables further expand its addressable market. Karapetjanc expects further growth as both market momentum and fundamentals align. "Strong demand and innovation point to significant upside as the platform continues to scale," he asserts.

Sholanke Dele, market strategist, is cautious about the sustainability of this rally. He stresses that mixed momentum readings and low ADX warn of a weak underlying trend. Recent gains may reflect short-term enthusiasm rather than a solid longer-term shift. "Until stronger trend confirmation appears, I remain defensive on upside potential here," states Dele.

Mixed momentum as price outpaces key support and enters overbought zone

Hims & Hers Health is trading above the 20-day, 50-day, and 200-day moving averages ($29.57, $31.91, and $28.94), with the price also holding above the Ichimoku Kijun support at $30.97. This alignment confirms a bullish structure in the short, medium, and long term, as well as a prevailing uptrend, with resistance at $33.14 and support at $31.91. Momentum signals are mixed: the MACD currently issues a Strong Sell, indicating weak momentum, and the ADX at 11.65 signals a neutral trend. The RSI at 53.74 issues a Buy, but both the Stochastic RSI at 100 and the CCI at 116.57 flag overbought conditions. Bull/Bear Power reads 3.11, showing buyers dominate intraday activity, though it is also categorized as overbought. The price is near the high of today’s $30.8–$33.14 range, and intraday volatility stands at 7.60%. There is notable strength toward the highs in today’s session, even though momentum readings diverge.

Previously it was reported that Hims & Hers Health maintained technical strength and above-average volatility amid heightened legal scrutiny and mixed signals. The latest earnings-driven rally adds a strong fundamental backdrop to the technical picture, reinforcing the need to monitor the $31.91 support and $33.14 resistance as key levels for potential breakout or breakdown scenarios in the days ahead.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.